Healthcare provider profile · identity verified

John Hayes, MD

Family Practice · SALEM, OR · NPI 1700975174

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	415	126
Lisinopril	Lisinopril	319	112
Losartan Potassium	Losartan Potassium	189	64
Simvastatin	Simvastatin	180	53
Amlodipine Besylate	Amlodipine Besylate	171	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	171	29
Gabapentin	Gabapentin	170	43
Levothyroxine Sodium	Levothyroxine Sodium	168	48
Metformin Hcl	Metformin Hcl	157	54
Potassium Chloride	Potassium Chloride	157	56
Hydrochlorothiazide	Hydrochlorothiazide	155	50
Pantoprazole Sodium	Pantoprazole Sodium	136	50
Oxycodone Hcl	Oxycodone Hcl	129	27
Glipizide	Glipizide	125	46
Tamsulosin Hcl	Tamsulosin Hcl	125	44
Metoprolol Tartrate	Metoprolol Tartrate	118	43
Atenolol	Atenolol	115	34
Trazodone Hcl	Trazodone Hcl	106	33
Albuterol Sulfate Hfa	Albuterol Sulfate	101	44
Tramadol Hcl	Tramadol Hcl	77	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	25
Pradaxa	Dabigatran Etexilate Mesylate	72	30
Allopurinol	Allopurinol	70	23
Metformin Hcl Er	Metformin Hcl	70	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	22
Warfarin Sodium	Warfarin Sodium	68	22
Furosemide	Furosemide	61	27
Carvedilol	Carvedilol	59	20
Mirtazapine	Mirtazapine	52	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	52	suppressed
Omeprazole	Omeprazole	51	17
Ibuprofen	Ibuprofen	50	16
Sertraline Hcl	Sertraline Hcl	50	18
Pregabalin	Pregabalin	49	13
Alendronate Sodium	Alendronate Sodium	48	15
Donepezil Hcl	Donepezil Hcl	46	12
Jardiance	Empagliflozin	46	17
Morphine Sulfate Er	Morphine Sulfate	46	suppressed
Humulin N	Insulin Nph Human Isophane	45	16
Duloxetine Hcl	Duloxetine Hcl	43	15
Spiriva Respimat	Tiotropium Bromide	43	14
Clopidogrel	Clopidogrel Bisulfate	41	16
Meloxicam	Meloxicam	41	14
Rosuvastatin Calcium	Rosuvastatin Calcium	41	17
Montelukast Sodium	Montelukast Sodium	40	13
Fentanyl	Fentanyl	39	suppressed
Lorazepam	Lorazepam	37	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	15
Fluoxetine Hcl	Fluoxetine Hcl	36	14
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	36	14
Triamcinolone Acetonide	Triamcinolone Acetonide	35	20
Alvesco	Ciclesonide	34	13
Metoprolol Succinate	Metoprolol Succinate	34	13
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Humulin R	Insulin Regular, Human	32	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	30	29
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	29	13
Lovastatin	Lovastatin	29	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Terazosin Hcl	Terazosin Hcl	28	11
Citalopram Hbr	Citalopram Hydrobromide	27	11
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	27	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	26	suppressed
Prednisone	Prednisone	26	18
Spironolactone	Spironolactone	26	11
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Finasteride	Finasteride	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	25
Famotidine	Famotidine	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Methocarbamol	Methocarbamol	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Nystatin	Nystatin	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Eliquis	Apixaban	16	suppressed
Morphine Sulfate	Morphine Sulfate	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	16
Nitroglycerin	Nitroglycerin	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Torsemide	Torsemide	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Estradiol	Estradiol	15	suppressed
Flecainide Acetate	Flecainide Acetate	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Baclofen	Baclofen	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Azithromycin	Azithromycin	13	12
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	12	suppressed
Naratriptan Hcl	Naratriptan Hcl	12	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error